Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.68 |
| ▸ | POLB | P06746 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.65 |
| ▸ | LMNA | P02545 | 4/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13254370 | 0.89 | KMT2A (0.65) | SMN1; SMN2POLBKMT2ALMNAALDH1A1 | |
| SCHEMBL7027267 | 0.83 | KMT2A (0.68) | POLBKMT2ALMNAALDH1A1MEN1 | |
| SCHEMBL7027668 | 0.80 | FABP1 (0.65) | ALDH1A1MAPK1GAAMAPT | |
| SCHEMBL7029577 | 0.77 | GPR183 (0.54) | SMN1; SMN2KMT2ALMNAALDH1A1MEN1 | |
| SCHEMBL7027996 | 0.76 | MEN1 (0.49) | KMT2AALDH1A1MEN1GAA | |
| SCHEMBL7028323 | 0.76 | POLB (0.50) | SMN1; SMN2POLBKMT2ALMNAMEN1 | |
| SCHEMBL6985771 | 0.74 | KMT2A (0.79) | SMN1; SMN2POLBKMT2ALMNAALDH1A1 | |
| SCHEMBL7029110 | 0.74 | PRKD3 (0.57) | SMN1; SMN2KMT2AMEN1CYP1A2CYP2C19 | |
| SCHEMBL7026165 | 0.74 | KCNH2 (0.69) | SMN1; SMN2KMT2AALDH1A1MEN1TDP1 | |
| SCHEMBL7022823 | 0.73 | PKM (0.64) | POLBKMT2ALMNAALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030130287-A1 | Piperidine and piperazine derivatives which function as 5-ht2a receptor antagonists | MERCK PATENT GMBH (DE) | 2003-07-10 | — | — | US | disclosed |
| EP-1246803-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES WHICH FUNCTION AS 5-HT 2A? RECEPTOR ANTAGONISTS | MERCK PATENT GmbH (DE) | 2002-10-09 | — | — | EP | disclosed |
| WO-2001051469-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES WHICH FUNCTION AS 5-HT2A RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2001-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130287-A1 | Piperidine and piperazine derivatives which function as 5-ht2a receptor antagonists | HTR2A, HTR1A, HTR5A | SMN1; SMN2 430/4885POLB 1282/4885KMT2A 472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.